hikma

Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis Medication across MENA Markets

• People and Community

Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis Medication across MENA Markets

AETOSWire August 25, 2022

Amman, Jordan — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with...

Read More Read more about Hikma and Adalvo Sign Exclusive Licensing Agreement to Commercialise Allergic Rhinitis Medication across MENA Markets

Hikma’s diversified business delivers resilient H1 performance

• People and Community

Hikma’s diversified business delivers resilient H1 performance

AETOSWire August 4, 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its...

Read More Read more about Hikma’s diversified business delivers resilient H1 performance

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

• People and Community

Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

AETOSWire July 18, 2022

London, United Kingdom — Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement...

Read More Read more about Hikma and Celltrion sign exclusive licensing agreement for YuflymaTM for the Middle East and North Africa region

Siggi Olafsson to step down as Chief Executive

• People and Community

Siggi Olafsson to step down as Chief Executive

AETOSWire May 24, 2022

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma) today announces that Siggi Olafsson has resigned as Chief...

Read More Read more about Siggi Olafsson to step down as Chief Executive

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

• People and Community

Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

AETOSWire April 29, 2022

London, England – Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical group, today provides an update on...

Read More Read more about Hikma continued strategic progress and updated full-year guidance following Custopharm acquisition

Hikma Ventures Participates in USD 44 Million Financing Round for Altibbi to Expand the Platform’s Reach across MENA

• People and Community

Hikma Ventures Participates in USD 44 Million Financing Round for Altibbi to Expand the Platform’s Reach across MENA

AETOSWire March 31, 2022

Jordan, Amman: Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, announces that its venture capital...

Read More Read more about Hikma Ventures Participates in USD 44 Million Financing Round for Altibbi to Expand the Platform’s Reach across MENA

Hikma delivers another year of profitable growth in 2021 and announces share buyback

• People and Community

Hikma delivers another year of profitable growth in 2021 and announces share buyback

AETOSWire February 24, 2022

London, United Kingdom-(AETOSWire) : Hikma Pharmaceuticals PLC (‘Hikma’ or ‘Group’), the multinational pharmaceutical company, today reports its...

Read More Read more about Hikma delivers another year of profitable growth in 2021 and announces share buyback

Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

• People and Community

Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

AETOSWire February 7, 2022

London, United Kingdom– (AETOSWire) Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces an exclusive licensing agreement with...

Read More Read more about Hikma expands licensing agreement with Celltrion for Remsima® subcutaneous formulation in MENA

Hikma signs license agreement with Medicine Patent Pool for molnupiravir

• People and Community

Hikma signs license agreement with Medicine Patent Pool for molnupiravir

AETOSWire January 20, 2022

London, United Kingdom, (AETOSWire) – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has...

Read More Read more about Hikma signs license agreement with Medicine Patent Pool for molnupiravir